We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Ian Walker
AstraZeneca PLC (AZN.LN) and Merck & Co. Inc. (MRK) said Wednesday that the European Commission has approved Lynparza as a monotherapy for the treatment of germline BRCA-mutated metastatic breast cancer.
AstraZeneca's executive vice president of oncology, Dave Fredrickson, said the approval enables Lynparza to provide patients throughout the EU with a targeted and oral chemotherapy-free treatment option for a difficult-to-treat cancer.
Advanced/metastatic breast cancer refers to Stage III and IV breast cancer, while BRCA are human genes that produce proteins responsible for repairing damaged DNA.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 10, 2019 02:42 ET (06:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
